2 independently checked trend briefs about this subject, newest first.
headlinez.news detected 2 source-qualified news clusters connected to Amgen between June 26, 2026 and July 3, 2026. They span 1 newsroom category and average 6.5 independent sources per brief.
This hub includes only briefs supported by at least four sources and passed by the site's verification gate. Raw or weak detections may exist but are excluded here. Topic matching is based on the entities and themes recorded with each brief; open a card to inspect its source links, publication time, verification label and velocity history. Read the methodology and editorial policy for the full rules.
Roche's experimental KRAS inhibitor has outperformed current standard treatments in a head-to-head late-stage clinical trial for lung cancer.
European regulators have recommended revoking marketing authorization for the Amgen drug Tavneos due to concerns regarding the reliability of study data.